ETOL-Elderly Study of the Efficiency of the Innovative Food Supplement in Elderly Adults (ETOL-Elderly)

June 19, 2023 updated by: Nutrition Institute, Slovenia

Study of the Efficiency of the Innovative Food Supplement in Improving Nutritional Status of Elderly Adults

The aim of this pilot study is to conduct a study on geriatric population in Slovenia (non-users of dietary supplements/medicines with vitamine D, vitamin B12 and protein) and assess deficiency of selected nutrients, and to investigate the efficiency of the innovative food supplement prototype in improving nutritional status of elderly adults.

Study Overview

Detailed Description

The main objective is to show that in the geriatric population regular use of investigation food supplement would improve nutritional status. The study should provide answers to the following main questions: (1) Is regular use of investigated product beneficial for improving serum vitamin D levels in elderly population? (2) Is regular use of investigated product beneficial for increasing daily protein intake in elderly population? (3) Is regular use of investigated product beneficial for improving vitamin B12 status in elderly population?

Study Type

Interventional

Enrollment (Actual)

40

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

63 years and older (Older Adult)

Accepts Healthy Volunteers

Yes

Description

Inclusion criteria:

  • Subject Informed consent form (ICF) is singed
  • Aged at least 65 at the time of the signature of ICF
  • A body mass index lower than 32 kg/m2
  • Willing to avoid a consumption supplementation with protein, vitamin D and vitamin B12 during the study
  • Willing to follow all study procedures, including attending all site visits (including blood sampling) and keeping a diary for using the product and six 24-hour dietary records (3x pre-intervention, 3x during last week of the intervention)

Exclusion criteria:

  • Medical treatment with Vitamin D and/or Vitamin B12
  • Supplementation with protein, vitamin D and/or vitamin B12 during least 2 months
  • Known drug and/or alcohol abuse
  • Known lactose/gluten intolerances/food allergies
  • Inadequate veins (in the opinion of the investigator) or known contraindication for venous blood withdrawal
  • Have chronic bowel disease (ulcerative colitis, Chron's disease, stomach or duodenal ulcer, chronic inflammation of the stomach or duodenum)
  • Have acute gastrointestinal infection with vomiting and / or diarrhea
  • Have planned general anaesthesia or colonoscopy at the time of the study
  • Have malabsorption syndrome
  • Less than 5 years after treatment for gastrointestinal cancer (stomach, duodenum or colon)
  • Have stomach or bowel resection
  • Do not have neat and functional teeth
  • Take regular or occasional laxative products
  • Use antacids (Rupurut / Rutacid / Talcit)
  • Mental incapacity that precludes adequate understanding or cooperation
  • Participation in another investigational study

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Quadruple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Placebo Comparator: Control group
Subjects taking control product
On day 1 subjects start with intervention on prearranged day. First dosage of test product is consumed during day 1 between regular meals (not as meal substitute). In the following days: continuation of consumption of test product once per day until end
Experimental: Active group
Subjects taking active product

On day 1 subjects start with intervention on prearranged day. First dosage of test product is consumed during day 1 between regular meals (not as meal substitute).

In the following days: continuation of consumption of test product once per day until end of the intervention. Subjects are recording daily consumption of the product. Intervention diet recording during last week of intervention (days 49-56): 3x24h dietary records (two days during weekday, one weekend day).

Intervention end on day 56 ±3 (fasted condition):

Measuring S-25-OH-VitD, S-VitB12, S-protein, S-albumin, S-CRP Measuring body weight & height Collecting data regarding the palatability of the product

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in serum vitamin D levels will be determined
Time Frame: 56 days
Serum level of 25-OH-vitamin D will be measured before and after the intervention for each individual.
56 days

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in dietary protein intake will be determined
Time Frame: 56 days
Dietary protein intake will be estimated before and after the intervention for each individual, using 3x24h food records.
56 days
Change in serum vitamin B12 levels will be determined
Time Frame: 56 days
Serum level of vitamin B12 will be measured before and after the intervention for each individual.
56 days
Malnutrition at baseline
Time Frame: baseline
Risks for malnutritition at baseline will be assessed using dietary records (3x24h food record: energy, protein and plasma concentration of 25-OH-D and vitamin B12.
baseline

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Mojca Miholič, MD, Researcher

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

February 20, 2020

Primary Completion (Actual)

May 5, 2020

Study Completion (Actual)

June 29, 2020

Study Registration Dates

First Submitted

December 13, 2022

First Submitted That Met QC Criteria

December 13, 2022

First Posted (Actual)

December 21, 2022

Study Record Updates

Last Update Posted (Actual)

June 22, 2023

Last Update Submitted That Met QC Criteria

June 19, 2023

Last Verified

June 1, 2023

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Vitamin B 12 Deficiency

Clinical Trials on Use of placebo food supplement

3
Subscribe